Imagine transforming near-total blindness into the ability to read every letter on an eye chart and tackle crossword puzzles – that's the astonishing reality for several patients who've received a revolutionary treatment from a California-based startup called Science Corp. This isn't just hype; it's a medical milestone that could redefine how we think about vision loss. But here's where it gets controversial: as we edge closer to blending human brains with technology, are we crossing ethical lines that society isn't ready to navigate?
Science Corp. has recently unveiled that multiple individuals suffering from severe vision impairments, as highlighted in discussions about global myopia trends predicting that half the world's population might have nearsightedness by 2050, have regained the capacity to decipher letters, numbers, and even entire book pages following implantation of their PRIMA ocular prosthesis. To put this in perspective, think of it like upgrading a faulty camera lens in your eyes – suddenly, the world comes back into focus.
This groundbreaking development was detailed in a recent publication from The New England Journal of Medicine. Despite the buzz, the company's CEO, Max Hodak, who is just 36 years old, discusses this achievement with a sense of calm nostalgia, as if it were ancient history, even though the news broke at the end of October.
Hodak, a biomedical engineer hailing from New York State, co-founded Elon Musk's Neuralink, where he once held the role of president. In 2021, he parted ways with Musk to launch Science Corp., dedicating the venture to reviving sight through brain-computer interfaces. These are innovative systems that connect the brain directly to computers, allowing electronic signals to bypass damaged parts of the body and restore functions. For beginners, picture it as a bridge between your brain's neural pathways and external tech, like a super-smart translator that helps your body communicate what your eyes can't.
During an interview at the Web Summit in Lisbon, where Hodak was a featured keynote speaker, he spoke in a style that's both scholarly and entrepreneurial – serious, quick, and deeply technical. When asked about his early fascination with brain-computer interfaces, as noted on his personal website, he explained that such a complex field intrigued him even as a child.
'Question: On your personal website, you mention that you were interested in brain-computer interfaces from a young age. That’s a complex topic for a child…'
'Answer: The brain is the core of your entire existence – it's the ultimate command center for every thought, feeling, and experience. It's the only organ that truly captivates me. The rest of the body is essentially a support system, designed to transport the brain, keep it alive, and enable its operations. This realization struck me very early on. And with brain-computer interfaces, we can achieve outcomes that traditional medicine simply can't match.'
'Q: How so?'
'A: By implanting a device into the motor cortex of the brain, within just 30 minutes, a patient with PRIMA can start playing video games. Individuals who were nearly blind – unable to even recognize faces – suddenly gain the ability to read every single letter on an eye chart and complete crossword puzzles. It's like flipping a switch from darkness to clarity.'
'Q: How much of what you dreamed about as a child is now a reality?'
'A: Quite a bit, actually. Just two decades ago, this was pure science fiction... but now, breakthroughs are unfolding at an incredible pace.'
'Q: Your company focuses on restoring vision. Can you explain how PRIMA works?'
'A: It's a compact chip. Under a microscope, it appears as a grid of tiny hexagonal units, each functioning as a miniature solar panel. This implant is positioned beneath the retina at the back of the eye. It collaborates with special glasses equipped with a built-in camera that captures the external world and a laser projector that directs light into the eye.'
'Q: This is the basic hardware, but how is the information transmitted?'
'A: The camera captures live footage of the patient's environment. An infrared emitter then beams these images onto the implant behind the eye, where the data is pre-encoded into patterns for efficient transmission. When infrared light reaches the retina, it activates it, essentially turning PRIMA into an artificial photoreceptor that mimics the role of natural light-sensitive cells.'
This technology works best for those who had vision early in life. Their brains retain knowledge of sight, and the optic nerve remains intact, but the retina's light-sensing cells – the cones and rods responsible for detecting colors and shapes – have deteriorated due to various causes.
'Q: Which eye diseases could be treated with this approach?'
'A: Numerous conditions lead to the demise of cones and rods, including age-related macular degeneration (the focus of the PRIMA study published in the journal), retinitis pigmentosa, Stargardt disease, and in some instances, diabetic retinopathy. As long as the brain can process visual information and the retina stays linked to it – even if it's no longer responsive to light – our chip can directly stimulate the retina, effectively sidestepping the defunct cones and rods. For example, age-related macular degeneration affects central vision, making tasks like reading or driving difficult, and PRIMA offers a potential lifeline by restoring that lost visual pathway.'
'Q: So, it seems like you’ve taken a mechanical approach?'
'A: More like an electronic one, really. It succeeds because the brain operates as an information hub: we can engage with it through data streams.'
'Q: What’s it like for you and your team when you see a patient able to read words again, after years of being unable to do so?'
'A: My maternal grandfather battled retinitis pigmentosa, so I grew up witnessing the challenges of blindness firsthand. Witnessing this innovation help real patients is incredibly thrilling.'
'Q: Was your grandfather able to treat his condition?'
'A: He relied on a magnifying glass to try and compensate for his declining vision.'
'Q: I suppose it wasn’t an efficient method…'
'A: Obviously, it fell short. That's why seeing PRIMA featured on the cover of Time magazine was so exhilarating for me – I remember these kinds of devices being showcased on Wired covers back then, promising breakthroughs that never materialized. And now, 25 years later, they truly deliver.'
'Q: Perhaps this is a poorly-worded question, but let me ask it: how far are we from curing blindness?'
'A: I avoid saying 'curing blindness' because the restored vision doesn't match natural eyesight. Patients would still prefer their original sight. However, in the next five to seven years, we might reach levels of normal visual sharpness.'
'Q: Are we talking about the same resolution that the eye naturally has?'
'A: I believe that within one or two iterations of devices, we'll achieve 20/20 vision. Yet, one element we still lack is color perception. Currently, PRIMA delivers black-and-white images. I anticipate adding color soon, with reds and greens being simpler to implement than blues. By the start of the next decade, patients could have options nearly indistinguishable from their natural vision.'
'Q: Excuse my impertinence, but what about curing blindness?'
'A: Absolutely, we must clarify that blindness stems from diverse causes. Degeneration of cones and rods is just one; another is optic nerve damage, often from glaucoma. Our method doesn't address glaucoma, which would require a different strategy to rebuild the retina-brain connection.'
And this is the part most people miss: the broader implications of brain-computer interfaces extend far beyond vision. From hearing aids like cochlear implants to brain stimulation for Parkinson's disease, these technologies are evolving rapidly. For many enthusiasts, the field is synonymous with motor cortex decoders, as seen in Neuralink's work, where implants act like brain-operated computers. But it's just one facet of a vast realm.
'Q: Is surgery necessary for all these applications?'
'A: In reality, I foresee many advancements becoming non-invasive, using wearable devices. Decoding speech, for instance, might not require implants at all.'
'Q: What can we expect in the coming years from a growing sector like this?'
'A: Broadening our view of brain engineering, we might wonder: after a stroke damages brain regions responsible for certain abilities, can we restore them? This ventures into unconventional brain-computer interface territory.'
'Q: Is this already being explored?'
'A: Yes, research is underway. It's been tested in animals, and I predict human applications soon.'
'Q: How long until PRIMA is approved by regulators in the United States and Europe?'
'A: We're in the review phase in Europe. The U.S. FDA process is slower, so European patients may access it first.'
'Q: When do you expect the device to be available in Europe?'
'A: We anticipate launching it on the market next year.'
As we stand on the brink of these transformative technologies, it's worth pondering: are we truly 'curing' disabilities, or merely enhancing them in ways that raise new questions about human augmentation? Could implanting devices in the brain lead to unforeseen ethical dilemmas, like privacy concerns or unequal access? And here's a controversial twist – some might argue that pursuing 'perfect' vision through tech distracts from preventing vision loss in the first place, like addressing environmental factors driving myopia. What are your thoughts? Do you see this as an exciting leap forward, or a slippery slope into sci-fi territory? Share your opinions in the comments below – let's discuss!
Sign up for our weekly newsletter to receive more English-language news from EL PAÍS USA Edition.
